Hypericum para Mitigación de la esteatosis hepática
Hypericum forrestii — 6 estudios científicos revisados
Preliminary¿Sirve Hypericum para mitigación de la esteatosis hepática?
El compuesto Hypercohin A actúa como un inhibidor de la proteína mTOR, lo que ayuda a suprimir la lipogénesis de novo (creación de nuevas grasas) y a restringir la ferroptosis en los hepatocitos [PMID 41687533].
Compuestos activos involucrados: Alcaloides, Flavonoides, Hipercoina, Hiperina, Terpenoides, Acilfloroglucinol, Floroglucinol, Hiperforina, Isopreno
Evidencia Científica
Los siguientes estudios han investigado la relación entre Hypericum y mitigación de la esteatosis hepática:
Hypercohin A alleviates hepatic steatosis via the mammalian target of rapamycin (mTOR)-dependent suppression of de novo lipogenesis and ferroptosis.
BACKGROUND AND PURPOSE: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of liver-related morbidity and mortality. Despite the fact, no effective drug was available in clinic. The mammalian target of rapamycin (mTOR) is a key regulator of lipid metabolism, which is regarded as a promising therapeutic target for MASLD. This study aims to screen polycyclic polyprenylated acylphloroglucinols (PPAPs) from Hypericum forrestii (Chitt.) N. Robson with the potential for treating MASLD, and further investigate the molecular target and underlying mechanism.
PubMed: 41687533Herbal medicines in the treatment of psychiatric disorders: 10-year updated review.
This paper provides a 10-year update of the 2007 systematic review of herbal medicines studied in a broad range of psychiatric disorders, including depression, anxiety, obsessive-compulsive, seasonal affective, bipolar, psychotic, phobic, somatoform, and attention-deficit hyperactivity disorders. Ovid Medline, PubMed, and the Cochrane Library were searched for herbal medicines with both pharmacological and clinical evidence of psychotropic activity. This updated review now covers clinical trial evidence for 24 herbal medicines in 11 psychiatric disorders. High-quality evidence was found to exi
PubMed: 29575228Adverse effects of herbal medicines: an overview of systematic reviews.
This overview of systematic reviews (SRs) aims to evaluate critically the evidence regarding the adverse effects of herbal medicines (HMs). Five electronic databases were searched to identify all relevant SRs, with 50 SRs of 50 different HMs meeting our inclusion criteria. Most had only minor weaknesses in methods. Serious adverse effects were noted only for four HMs: Herbae pulvis standardisatus, Larrea tridentate, Piper methysticum and Cassia senna. The most severe adverse effects were liver or kidney damage, colon perforation, carcinoma, coma and death.
PubMed: 23472485Ethnobotanical and ethnomedicinal research into medicinal plants in the Mt Stara Planina region (south-eastern Serbia, Western Balkans).
BACKGROUND: Ethnobotanical research in Southeast Europe-one of the most important European hotspots for biocultural diversity-is significant for the acquisition of Traditional Ecological Knowledge related to plants as well as for encouraging the development of local environments. The current ethnobotanical research was conducted in the region of Mt Stara Planina (south-eastern Serbia), which is characterised by rich phytodiversity with a large number of endemic and relict plant species. The aim of the study was to document the diversity of uses of medicinal plants and of traditional knowledge
PubMed: 38200599Hypericum species: An analysis on the patent technologies.
Hypericum (Hypericaceae) is a genus that comprises approximately 500 species around the world. The industrial relevance of these plants is based on the occurence of specialized metabolites that exhibit a range of pharmaceutical potential. Besides that, several species are relevant due to their ornamental value. Taking to account the vast market worth of products and processes involving Hypericum, the present study aims to provide a comprehensive overview of patents concerning this subject between 2007and 2017. For this purpose, a survey was performed in free databases (Espacenet®, PatentScope®
PubMed: 31629873Seguridad y Precauciones
El uso de Hypericum forrestii debe abordarse con extrema precaución debido a su compleja composición química, que incluye compuestos como la hiperina y diversos poliprenilados acilfloroglucinoles (PPAPs). En el caso de mujeres embarazadas y en periodo de lactancia, no existe evidencia científica suficiente que garantice la seguridad del uso de esta planta; por el contrario, existe un riesgo potencial de transferencia de compuestos bioactivos a través de la placenta o la leche materna, lo que podría alterar el desarrollo fetal o neonatal. Dado que los componentes de Hypericum pueden actuar sobre vías de señalización celular críticas, como la inhibición de la proteína tirosina fosfatasa 1B (PTP1B) [PMID 34111550] o la vía mTOR [PMID 41687533], el uso durante el embarazo es desaconsejado para evitar interferencias en el desarrollo fisiológico normal. En niños menores de 12 años, la seguridad no ha sido establecida y el riesgo de efectos sobre el sistema nervioso central y el metabolismo es elevado, por lo que se debe evitar su administración en poblaciones pediátricas. Uno de los riesgos más críticos es la interacción farmacológica. Los compuestos de Hypericum, particularmente aquellos con similitud estructural a la hiperforina, son conocidos inductores de las enzimas del citocromo P450 (específicamente CYP3A4) y de la glicoproteína P.
Perfil completo: Ver todos los usos y evidencia de Hypericum →